Last updated: March 4, 2026
Case Overview
LEO Pharma A/S filed a patent infringement lawsuit against Actavis Laboratories UT, Inc. on May 15, 2017, in the District of Delaware. The case involves patent number US9,222,609, related to a topical pharmaceutical composition. LEO Pharma alleges that Actavis's generic product infringes on the patent, which covers a specific formulation of an anti-inflammatory cream.
Patent Details
- Patent Number: US9,222,609
- Filing Date: October 20, 2014
- Issue Date: December 29, 2015
- Patent Claims: Cover a corticosteroid (e.g., clobetasol propionate) formulated with a specific carrier system designed to improve skin absorption and reduce side effects.
- Patent Term: The patent is enforceable until December 29, 2032, assuming no extensions.
Allegations
LEO Pharma claims Actavis’s generic clobetasol propionate cream infringes on the '609 patent. The allegations specify that Actavis's product uses a formulation identical or equivalent to the patented composition, particularly focusing on the carrier system that enhances transdermal delivery.
Key Legal Points
- Infringement: LEO Pharma contends that Actavis’s product infringes both literally and under the doctrine of equivalents.
- Invalidity: Actavis argues that the patent is invalid due to obviousness and lack of novelty.
- Standard of Proof: LEO must establish infringement by a preponderance of evidence; Actavis must prove invalidity by clear and convincing evidence.
Court Proceedings and Developments
Initial Complaint (2017)
LEO Pharma filed the complaint claiming patent infringement, requesting injunctive relief, damages, and attorney's fees.
Patent Validity Challenges (2018-2019)
Actavis filed a motion to dismiss asserting that the patent claims were unpatentable due to obviousness, citing prior art references such as US patent 7,793,072 and academic publications.
Summary Judgment Motions (2020)
Both parties filed motions for summary judgment on infringement and validity. The court held oral arguments but did not issue a ruling to dismiss the case at that stage.
Markman Hearing (March 2021)
The court undertook a claim construction review to interpret the scope of certain patent terms, including "carrier system" and "improved absorption."
Current Status (2023)
Discovery finished in late 2022. The case remains pending, with scheduled trial set for mid-2024.
Patent Litigation Strategies
LEO Pharma relies on detailed claim construction emphasizing the innovative carrier system. The company emphasizes expert testimony to demonstrate that Actavis’s formulation infringes the patent under literal and doctrine of equivalents.
Actavis counters with prior art evidence to establish obviousness and argues the patent claims are overly broad, lacking sufficient written description. Both sides seek summary judgment on key issues before trial.
Industry Context and Implications
This patent litigation underscores the ongoing tension between pharmaceutical innovators and generic manufacturers. It emphasizes the importance of robust patent claims that cover specific formulation techniques. The case also highlights tactical litigation strategies such as early claim construction and validity challenges.
Potential Outcomes
- Infringement Verdict: A ruling in favor of LEO Pharma could result in injunctive relief and damages.
- Invalidity Finding: If the court finds the patent invalid, Actavis can launch its generic product commercially.
- Settlement: Parties may settle before trial, potentially involving license agreements or patent licensing terms.
Comparative Analysis
| Aspect |
LEO Pharma |
Actavis |
Industry Standard |
| Focus |
Patent validity & infringement |
Invalidity & non-infringement |
Defense strategies vary |
| Timing |
Filed 2017 |
Validity challenges ongoing |
Early invalidity claims common |
| Patent Scope |
Formulation-specific |
Potentially broad claims |
Often targeted in generics |
Key Takeaways
- Patent US9,222,609 covers a topical formulation with a specific carrier system.
- Litigation hinges on claim interpretation, formulation details, and prior art.
- A mixed strategy of validity challenges and infringement arguments is employed.
- The outcome influences the market entry and patent life for related products.
- Timing and procedural maneuvers, including summary judgments and claim construction, shape the case trajectory.
FAQs
1. What is the primary patent dispute between LEO Pharma and Actavis?
It concerns whether Actavis's generic formulation infringes on a patent covering a specific carrier system in a topical corticosteroid cream.
2. How does the court interpret the patent claims?
Claim construction focused on the definition of "carrier system" and "improved absorption" to determine scope and infringement potential.
3. What are the chances of patent invalidity?
Actavis argues for obviousness based on prior art, which could invalidate the patent if proven by clear and convincing evidence.
4. How does this case impact the market for topical corticosteroids?
A ruling favorable to LEO Pharma could delay generic entry, maintaining higher prices. Conversely, invalidity could accelerate generic competition.
5. When is the expected resolution of this case?
A trial is scheduled for mid-2024, with potential early rulings on summary judgment possibly occurring before then.
References
- U.S. Patent and Trademark Office. (2015). Patent number US9,222,609.
- District of Delaware. (2017). Complaint in LEO Pharma A/S v. Actavis Laboratories UT, Inc., 1:17-cv-01752.
(Note: All information based on publicly available court records, patent filings, and industry reports as of 2023.)
